2025-06-09-花旗集团-LENZ治疗公司（LENZ）_LENZ治疗公司（LENZ.O）_增加上行90天催化剂观察_10页_255kb

Summary of Citi Research Report on LENZ Therapeutics Inc

Key Recommendation

• Upside Buy/High Risk rating based on high volatility and drug development uncertainties.
• Target Price: $45.00, representing a 40.8% expected share price return from current $31.96.

Catalyst Watch

• Event: FDA approval of LNZ100 (aceclidine) for presbyopia.
• Expected Date: August 8, 2025.
• Probability: High likelihood, no major issues flagged in FDA meeting.
• Impact: Expected to provide a value inflection point.

Valuation Analysis

• Method: Discounted cash flow (DCF) analysis using a weighted average cost of capital (WACC) of 10%.
• Terminal Growth: Assumed -10% after 2039 patent expiration.
• Peak Sales: $630M by 2039 in base case.

Product Details

• LNZ100: Treatment for presbyopia with Phase 2 and 3 data showing superior durability (up to ~10 hours vs. Vuity's ~6 hours) and no safety concerns.
• Market Potential: 95% probability of US approval, 85% in EU, 70% in China.

Risks

• High Risk Factors:
  • Failure to receive FDA approval.
  • Emergence of unexpected safety signals.
  • Insufficient market education leading to sales below expectations.

Financial Projections

• EPS (2024-2025): Expected losses ranging from -$0.53 to -$3.07 per share.
• Long-Term: Potential recovery to -$0.80 per share by 2027, contingent on success of LNZ100.

Investment Thesis

• Opportunity in a highly derisked, near-commercial product with strong management team.